Search

Displaying results 3071 - 3080 of 10000 in total
  1. Drug

    Nadofaragene firadenovec

    go.drugbank.com/drugs/DB17381
    ApprovedInvestigational

    [A255111] Nadofaragene firadenovec is formulated with an excipient (Syn-3) that facilitates gene transfer across the urothelium and promotes the transduction of IFNα2b. … It is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat.

  2. Drug

    Rescinnamine

    go.drugbank.com/drugs/DB01180
    Approved

    Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from _Rauwolfia serpentina_ and other species of _Rauwolfia_.

  3. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. … [L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020.

  4. Drug

    Eritoran

    go.drugbank.com/drugs/DB04933
    Investigational

    Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

    Categories: Toll-Like Receptor 4, antagonists & inhibitors
  5. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.

  6. Drug

    Peginterferon beta-1a

    go.drugbank.com/drugs/DB09122
    ApprovedInvestigational

    [A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. … [L31428] Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.

    Categories: Interferon Type I, Compounds used in a research, industrial, or household setting
  7. Drug

    Oxitriptan

    go.drugbank.com/drugs/DB02959
    ApprovedInvestigationalNutraceuticalWithdrawn

    the United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication … More study is needed to determine efficacy in treating depression.

  8. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission

  9. Drug

    Lopinavir

    go.drugbank.com/drugs/DB01601
    ApprovedInvestigational

    Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. … [L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's

    Categories: Antivirals used in combination for the treatment of HIV infections
  10. Drug

    Crotalus adamanteus antivenin

    go.drugbank.com/drugs/DB13893
    Approved

    Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. … It is intravenously administered to limit systemic toxicity [FDA label].